Pharming Group to report third quarter 2024 financial results on October 24
October 10, 2024 02:00 ET
|
Pharming Group N.V.
Leiden, the Netherlands, October 10, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) third quarter 2024 financial...
Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation
October 10, 2024 01:00 ET
|
Pharming Group N.V.
Proof of concept clinical trial will evaluate leniolisib in PIDs with immune dysregulation linked to altered PI3Kẟ signaling in lymphocytes PIDs to include ALPS-FAS, CTLA4 haploinsufficiency, NFKB1...
Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)
September 26, 2024 01:00 ET
|
Pharming Group N.V.
For media and investors only Indicated for adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Leiden, the...
Pharming Group to participate in September investor conferences
September 04, 2024 01:00 ET
|
Pharming Group N.V.
Leiden, the Netherlands, September 4, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor...
Pharming Group reports second quarter and first half 2024 financial results and provides business update
August 01, 2024 01:00 ET
|
Pharming Group N.V.
Second quarter 2024 total revenues increased by 35% to US$74.1 million, compared to the second quarter 2023, driven by strong RUCONEST® and Joenja® revenue growthRUCONEST® second quarter revenue...
Pharming Group to report second quarter and first half 2024 financial results on August 1
July 18, 2024 02:00 ET
|
Pharming Group N.V.
Leiden, the Netherlands, July 18, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) second quarter and first half 2024...
Pharming Group to participate in June investor conferences
June 03, 2024 02:00 ET
|
Pharming Group N.V.
Leiden, the Netherlands, June 3, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor...
Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union
May 30, 2024 16:44 ET
|
Pharming Group N.V.
Leiden, the Netherlands, May 30, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today an update on the ongoing review of its Marketing...
Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders
May 21, 2024 11:30 ET
|
Pharming Group N.V.
Leiden, the Netherlands, May 21, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM/Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM) held today,...
Pharming Group to participate in May investor conference
May 20, 2024 02:00 ET
|
Pharming Group N.V.
Leiden, the Netherlands, May 20, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor...